BRK-B vs MMC

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.

Marsh & McLennan Companies (MMC) trades at a premium valuation with solid long-term profitability and a disciplined capital allocation track record, but faces near-term headwinds reflected in flat year-over-year earnings growth and weakening quarterly EPS momentum. The stock has significantly underperformed over the past year (-16.1%) and six months (-20.3%), lagging both its historical performance and several peers in the Financial Services sector, despite consistent earnings beats over the last 25 quarters. While its ROE of 28.73% and operating margin of 19.24% are strong relative to sector averages, elevated leverage (Debt/Equity: 1.40) and insider selling activity raise caution. Analysts broadly concur with a 'hold' rating and imply 17% upside to a $214.26 target, suggesting limited near-term catalysts despite attractive relative fundamentals.